Corcept Therapeutics (HAM:HTD) Change In Receivables: €19.6 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:HTD Corcept Therapeutics Inc HAM:HTD
86 GF Score
Price €77.78
GF Value €54.73
! 8 Warning Signs
View Full Analysis

What is Corcept Therapeutics Change In Receivables?

Corcept Therapeutics HAM:HTD -0.51% 86 Change In Receivables is €19.6 Mil as of Mar. 2026. GuruFocus rates HAM:HTD with a GF Score™ of 86/100 and a GF Value™ of €54.73. The stock has 8 warning signs investors should review.

Corcept Therapeutics's change in receivables for the quarter that ended in Mar. 2026 was €17.9 Mil. It means Corcept Therapeutics's Accounts Receivable declined by €17.9 Mil from Dec. 2025 to Mar. 2026 .

Corcept Therapeutics's change in receivables for the fiscal year that ended in Dec. 2025 was €-5.0 Mil. It means Corcept Therapeutics's Accounts Receivable increased by €5.0 Mil from Dec. 2024 to Dec. 2025 .

Corcept Therapeutics's Accounts Receivable for the quarter that ended in Mar. 2026 was €33.8 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Corcept Therapeutics's Days Sales Outstanding for the three months ended in Mar. 2026 was 21.62.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Corcept Therapeutics's liquidation value for the three months ended in Mar. 2026 was €170.4 Mil.

Corcept Therapeutics  (HAM:HTD) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Corcept Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=33.797/142.641*91
=21.62

2. In Ben Graham's calculation of liquidation value, Corcept Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Corcept Therapeutics's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=292.529-153.013+0.75 * 33.797+0.5 * 11.15
=170.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics Change In Receivables Related Terms

Corcept Therapeutics Change In Receivables Historical Data

* Premium members only.

The historical data trend for Corcept Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics Change In Receivables Chart

Corcept Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.26 -16.46 -9.23 1.10 -4.96

Corcept Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.26 -2.38 -4.31 8.41 17.92
HAM:HTD
86GF Score
Corcept Therapeutics Inc HAM:HTD
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corcept Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €19.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of €19.6 Mil mean?
Corcept Therapeutics (HAM:HTD) has a Change In Receivables of €19.6 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Corcept Therapeutics and its competitors.
Is Corcept Therapeutics' Change In Receivables too high?
Corcept Therapeutics' current Change In Receivables is €19.6 Mil. Overall, Corcept Therapeutics has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Change In Receivables compare to PRAX and IBRX?
Corcept Therapeutics' Change In Receivables of €19.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Corcept Therapeutics and its competitors. Corcept Therapeutics's current Change In Receivables is €19.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Corcept Therapeutics (HAM:HTD) has a current Change In Receivables of €19.6 Mil. The stock's GF Value™ is €54.73, compared to a current price of €77.78 — trading 42.1% above its estimated fair value. The current Change In Receivables is €19.6 Mil. Corcept Therapeutics' overall GF Score™ is 86/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Corcept Therapeutics (HAM:HTD), the current Change In Receivables is €19.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corcept Therapeutics (HAM:HTD) Overvalued in 2026?

Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued. The current stock price of €77.78 is trading 42.1% above its estimated GF Value™ of €54.73.

Key valuation signals for HAM:HTD:

  • Change In Receivables: €19.6 Mil
  • GF Value™: €54.73 vs. price of €77.78 (42.1% above fair value)
  • GF Score™: 86/100 with 8 warning signs

No single metric tells the full story. See the HAM:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corcept Therapeutics Business Description

Address 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
86GF Score

Get the complete analysis for HAM:HTD

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€77.78
Price
€54.73
GF Value